1.
Blood
; 2024 04 24.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38657242
RESUMEN
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.